Soligenix, Inc. SEC filings SNGX
Soligenix, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Dec 3, 2008. Its latest annual report, Form ARS, was filed on Aug 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (bylaw or fiscal year change, shareholder vote results, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 3, 2026 | — |
| DEF 14A | Proxy statement | Aug 3, 2026 | Sep 17, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 21, 2026 | Sep 17, 2026 |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| DEF 14A | Proxy statement | May 5, 2025 | Jun 20, 2025 |
| DEFA14A | Additional proxy material | May 29, 2024 | — |
| DEFA14A | Additional proxy material | May 28, 2024 | — |
| DEFA14A | Additional proxy material | May 22, 2024 | — |
| DEFA14A | Additional proxy material | May 17, 2024 | — |
| DEFA14A | Additional proxy material | May 15, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | May 23, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2024 | May 23, 2024 |
| DEFA14A | Additional proxy material | Oct 17, 2023 | — |
| DEFA14A | Additional proxy material | Oct 17, 2023 | — |
| DEFA14A | Additional proxy material | Oct 16, 2023 | — |
| DEFA14A | Additional proxy material | Oct 13, 2023 | — |
| DEFA14A | Additional proxy material | Oct 12, 2023 | — |
| DEFA14A | Additional proxy material | Oct 12, 2023 | — |
| DEFA14A | Additional proxy material | Sep 22, 2023 | — |
| DEFA14A | Additional proxy material | Sep 15, 2023 | — |
| DEFA14A | Additional proxy material | Aug 7, 2023 | — |
| DEF 14A | Proxy statement | Aug 7, 2023 | Sep 21, 2023 |
| DEFA14A | Additional proxy material | Jan 11, 2023 | — |
| DEF 14A | Proxy statement | Jan 6, 2023 | Feb 8, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2022 | Feb 8, 2023 |
| DEFA14A | Additional proxy material | Nov 16, 2022 | — |
| DEFA14A | Additional proxy material | Nov 15, 2022 | — |
| DEFA14A | Additional proxy material | Nov 14, 2022 | — |
| DEFA14A | Additional proxy material | Nov 9, 2022 | — |
| DEFA14A | Additional proxy material | Oct 5, 2022 | — |
| DEFA14A | Additional proxy material | Sep 13, 2022 | — |
| DEFA14A | Additional proxy material | Aug 9, 2022 | — |
| DEF 14A | Proxy statement | Aug 5, 2022 | Sep 22, 2022 |
| PRE 14A | Preliminary proxy statement | Jul 26, 2022 | Sep 22, 2022 |
| DEFA14A | Additional proxy material | Aug 10, 2021 | — |
| DEF 14A | Proxy statement | Aug 10, 2021 | Sep 23, 2021 |
| DEFA14A | Additional proxy material | Nov 25, 2020 | — |
| DEF 14A | Proxy statement | Nov 6, 2020 | Nov 23, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 23, 2020 | Oct 23, 2020 |
| DEFA14A | Additional proxy material | Aug 13, 2020 | — |
| DEFA14A | Additional proxy material | Aug 7, 2020 | — |
| DEF 14A | Proxy statement | Aug 7, 2020 | Sep 16, 2020 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2020 | Sep 16, 2020 |
| DEFA14A | Additional proxy material | Jul 26, 2019 | — |
| DEF 14A | Proxy statement | Jul 26, 2019 | Sep 6, 2019 |
| DEFA14A | Additional proxy material | Aug 10, 2018 | — |
| DEF 14A | Proxy statement | Aug 10, 2018 | Sep 27, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2018 | Jul 31, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 8, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2017 | Apr 18, 2017 |
| DEFA14A | Additional proxy material | May 2, 2016 | — |
| DEF 14A | Proxy statement | May 2, 2016 | Jun 16, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Jun 9, 2015 | — |
| DEFA14A | Additional proxy material | May 1, 2015 | — |
| DEF 14A | Proxy statement | May 1, 2015 | Jun 18, 2015 |
| DEFA14A | Additional proxy material | May 8, 2014 | — |
| DEF 14A | Proxy statement | May 8, 2014 | Jun 19, 2014 |
| DEF 14A | Proxy statement | Aug 14, 2013 | Aug 13, 2013 |
| DEFA14A | Additional proxy material | May 11, 2012 | — |
| DEF 14A | Proxy statement | May 11, 2012 | May 11, 2012 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2012 | Apr 16, 2012 |
| DEF 14A | Proxy statement | May 10, 2011 | May 10, 2011 |
| DEF 14A | Proxy statement | Aug 11, 2010 | Jun 30, 2010 |
| DEFA14A | Additional proxy material | Aug 11, 2010 | — |
| PRE 14A | Preliminary proxy statement | Jul 21, 2010 | Jul 21, 2010 |
| DEFA14A | Additional proxy material | Apr 24, 2009 | — |
| DEF 14A | Proxy statement | Apr 16, 2009 | Apr 16, 2009 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2009 | Apr 2, 2009 |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 812796
- Former names
- SOLIGENIX, INC. (until Nov 2, 2026); DOR BIOPHARMA INC (until Sep 29, 2009); ENDOREX CORP (until Oct 24, 2001); IMMUNOTHERAPEUTICS INC (until Apr 30, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.